ENZC (Enzolytics) OCF Margin %: -866.67% (As of Jun. 2011)


What is Enzolytics OCF Margin %?

Enzolytics ENZC -9.09% OCF Margin % is -866.67% as of Jun. 2011.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Enzolytics's Cash Flow from Operations for the three months ended in Jun. 2011 was $-0.13 Mil. Enzolytics's Revenue for the three months ended in Jun. 2011 was $0.02 Mil. Therefore, Enzolytics's OCF Margin % for the quarter that ended in Jun. 2011 was -866.67%.

As of today, Enzolytics's current OCF Yield % is -7.22%.

The historical rank and industry rank for Enzolytics's OCF Margin % or its related term are showing as below:

ENZC' s OCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -758.7

ENZC's OCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -66.52 vs ENZC: -758.70

Enzolytics OCF Margin % Related Terms

Enzolytics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Enzolytics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics OCF Margin % Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
OCF Margin %
0.00 0.00 -2,473.33 -1,108.11

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,625.00 -553.85 -316.67 -1,816.67 -866.67

Enzolytics OCF Margin % Competitor Comparison

For the Biotechnology subindustry, Enzolytics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzolytics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzolytics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Enzolytics's OCF Margin % falls into.


Enzolytics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Enzolytics's OCF Margin for the fiscal year that ended in Dec. 2010 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2010 )/Revenue (A: Dec. 2010 )
=-0.41/0.037
=-1,108.11 %

Enzolytics's OCF Margin for the quarter that ended in Jun. 2011 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2011 )/Revenue (Q: Jun. 2011 )
=-0.13/0.015
=-866.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -866.67% mean?
Enzolytics (ENZC) has a OCF Margin % of -866.67% as of Jun. 2011. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Enzolytics and its competitors.
Is Enzolytics' OCF Margin % too high?
Enzolytics' current OCF Margin % is -866.67%.
How does Enzolytics' OCF Margin % compare to competitors?
Enzolytics' OCF Margin % of -866.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Enzolytics and its competitors. Enzolytics's current OCF Margin % is -866.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current OCF Margin % of -866.67%. The current OCF Margin % is -866.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Enzolytics (ENZC), the current OCF Margin % is -866.67% as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.